Literature DB >> 18792486

Laparoscopic cholecystectomy in elderly patients.

Yildirim Osman1, Menekse Ebru, Turan Umit, Oter Volkan, Karabeyoglu Melih, Kocer Belma, Bozkurt Betul, Cengiz Omer, Soran Atilla.   

Abstract

AIM: In this study, we hypothesize that LC is a safe procedure in a non-laparoscopic specialized general surgery unit in a teaching hospital. PATIENTS AND METHODS: We evaluated retrospectively the data of 286 patients that had symptomatic cholelithiasis and were operated on with LC. RESULTS AND
CONCLUSION: Fifty-four (18.9%) male and 232 (81.1%) female patients underwent LC. Morbidity in patients over 75 years was higher than in patients under 75 years. Mean hospitalization time was 1.5 days. LC is as safe in young patients as in patients at age ranging from 65 to 75 at a general surgery setting at a teaching facility. Although postoperative morbidity risk is higher in patients over the age of 75 years and diagnosed with symptomatic cholelithiasis, the main reason for increased morbidity is having an ASA score greater or equal to 3, and it is independent from age. In conclusion, LC can be performed in patients older than 75 years of age after giving them proper treatment for comorbidities (Tab. 1, Ref. 12).

Entities:  

Mesh:

Year:  2008        PMID: 18792486

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  2 in total

1.  Laparoscopic cholecystectomy in patients aged 60 years and over - our experience.

Authors:  D Serban; C Branescu; C Savlovschi; A P Purcărea; A El-Khatib; S A Balasescu; A Nica; A M Dascalu; G Vancea; S M Oprescu; C Tudor
Journal:  J Med Life       Date:  2016 Oct-Dec

2.  Perioperative outcomes after laparoscopic cholecystectomy in elderly patients: a systematic review and meta-analysis.

Authors:  Sivesh K Kamarajah; Santhosh Karri; James R Bundred; Richard P T Evans; Aaron Lin; Tania Kew; Chinenye Ekeozor; Susan L Powell; Pritam Singh; Ewen A Griffiths
Journal:  Surg Endosc       Date:  2020-07-13       Impact factor: 4.584

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.